X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8%
Fri, 24 Aug

ORCHID PHARMA LTD has announced its results for the quarter ended March 2018. Here is a detailed performance review of the same:

ORCHID PHARMA LTD Quarterly Financials

No. of Mths
Qtr. Ending
3
Mar-17*
3
Dec-17*
3
Mar-18*
QoQ ChangeYoY Change
Net SalesRs m2,0491,4421,5588.0%-24.0%
Other incomeRs m868414-83.1%-83.5%
TurnoverRs m2,1341,5261,5723.0%-26.4%
ExpensesRs m1,9921,3062,27273.9%14.0%
Gross profitRs m-521136-714-625.0%
DepreciationRs m349335326-2.7%-6.7%
InterestRs m1,2137620-100.0%-100.0%
Profit before taxRs m-1,997-877-1,025
TaxRs m-119-105-101
Profit after taxRs m-1,879-772-924
Gross profit margin%-25.49.4-45.8
Effective tax rate%5.911.99.9
Net profit margin%-88.0-50.6-58.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 24.0% on a year-on-year (YoY) basis. The expenses were up by 14.0% YoY during the same period.
  • The company's operating profit increased by 37.0% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 45.8% in 4QFY18 as against 25.4% in 4QFY17.
  • Depreciation charges and finance costs declined by 6.7% YoY and 100.0% YoY, respectively.
  • Other income declined by 83.5% YoY during the quarter.
  • Net profit for the quarter increased by 50.8% YoY. Net profit margins during the quarter increased from -88.0% in 4QFY17 to -58.8% in 4QFY18.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 8.0% on a quarter-on-quarter (QoQ) basis. The expenses were up by 73.9% QoQ during the same period.
  • The company's operating profit declined by 625.0% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 45.8% in 4QFY18 as against 9.4% in 3QFY17.
  • Net profit for the quarter declined by 19.6% QoQ, while net profit margins declined from -50.6% in 3QFY17 to -58.8% in 4QFY18.

To see how ORCHID PHARMA LTD has performed over the last eight quarters, please visit here.

ORCHID PHARMA LTD Share Price Performance

Over the last one year, ORCHID PHARMA LTD share price has moved up from Rs 20.2 to Rs 7.6, registering a Loss of Rs 12.7 or around 62.6%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 15,410.4 (down 0.1%). Over the last one year it has moved up from 13,226.3 to 15,410.4, a gain of 2,184 points (up 16.5%).

Overall, the S&P BSE SENSEX is up 21.5% over the year.

Current Valuations

At the current price of Rs 7.6, the price to book value (P/BV) ratio of ORCHID PHARMA LTD stands at 0.2 times.

Equitymaster requests your view! Post a comment on "ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8%". Click here!

  

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Dec 17, 2018 02:07 PM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS